Skip to main content

Table 1 Clinical characteristics of patients at onset

From: Associated factors with poor treatment response to initial glucocorticoid therapy in patients with adult-onset Still’s disease

 

All (n=71)

With the eventa (n=29)

Without the event (n=42)

p-value

Age, years, mean ± S.D.

51.6 ± 18.1

54.5 ± 18.9

49.6 ± 17.5

0.262

Female patients, %

70.4

69.0

71.4

0.823

Weight, kg, mean ± S.D.

56.6 ± 12.1

56.5 ± 9.55

56.6 ± 13.8

0.967

Fever (>39.0°C), %

59.2

72.4

50.0

0.059

Weight loss or fatigue, %

62.0

55.2

66.7

0.327

Myalgia, %

32.4

37.9

28.6

0.407

Rashes, %

77.5

79.3

76.2

0.757

Lymphadenopathy, %

71.8

75.9

69.0

0.530

Sore throat, %

70.4

75.9

66.7

0.404

Hepatosplenomegaly, %

60.6

69.0

54.8

0.229

Pericarditis, %

7.0

13.8

2.4

0.086

Serositis, %

12.7

27.6

2.4

0.003

Interstitial lung disease, %

7.0

10.3

4.8

0.327

Arthritis, %

66.2

72.4

63.4

0.430

Hemophagocytic syndrome, %

14.1

24.1

7.1

0.048

DIC, %

5.6

6.9

4.8

0.542

mSFS score, mean ± S.D.

3.25 ± 0.91

3.59 ± 0.91

3.02 ± 0.84

0.009

WBC, /μl, mean ± S.D.

13919 ± 7018

17097 ± 7087

11615 ± 6072

0.001

neutrophil, /μl, mean ± S.D.

11871 ± 6734

14855 ± 6832

9651 ± 5806

0.001

lymphocyte, /μl, mean ± S.D.

1033 ± 609

1022 ± 705

1042 ± 534

0.893

NLR, mean ± S.D.

15.27 ± 11.89

20.14 ± 13.72

11.56 ± 8.79

0.005

Hb, g/dl, mean ± S.D.

11.1 ± 1.7

11.2 ± 1.4

11.1 ± 1.9

0.866

Plt, ×104/μl, mean ± S.D.

27.2 ± 13.6

24.6 ± 11.6

29.1 ± 14.8

0.178

ESR, mean ± S.D.

84.5 ± 35.3

75.1 ± 35.2

90.2 ± 34.6

0.652

CRP, mg/dl, mean ± S.D.

12.7 ± 8.9

14.7 ± 8.8

11.2 ± 8.8

0.102

AST, U/l, median (interquartile range)

53.5 (30.0–85.0)

69.0 (51.0–137.0)

45.0 (23.0–82.0)

0.011

ALT, U/l, median (interquartile range)

43.3 (20.0–81.0)

47.5 (27.0–109.0)

34.0 (17.0–70.0)

0.081

LDH, U/l, median (interquartile range)

438 (230–670)

612 (390–928)

331 (198–547)

<0.001

Ferritin, ng/ml, median (interquartile range)

4548 (616–10,323)

5850 (3459–32,902)

1337 (428–7898)

0.001

IgG, mg/dl, mean ± S.D.

1551 ± 747

1372 ± 438

1687 ± 896

0.093

Modified Pouchot score, mean ± S.D.

6.25 ± 1.8

7.28 ± 1.62

5.55 ± 1.57

<0.001

Severity index, mean ± S.D.

3.32 ± 1.62

4.14 ± 1.64

2.76 ± 1.36

<0.001

Calendar year of the onset

2012.5 ± 4.1

2012.8 ± 4.3

2012.3 ± 4.1

0.745

  1. S.D. standard deviation, DIC disseminated intravascular coagulation, mSFS modified systemic feature score, WBC white blood cell, NLR neutrophil-lymphocyte ratio, Hb hemoglobin, Plt platelet count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, LDH lactate dehydrogenase, AST aspartate transferase, ALT alanine aminotransferase, Severity index severity index of Japanese Ministry of Health, Labour and Welfare
  2. aEvent of a poor treatment outcome, which was defined as failure to achieve remission or relapse after achieving remission within 4 weeks, followed by administration of two or more rounds of GC pulse therapy or of any other immunosuppressive drugs
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us